Rapastinel is expected to launch in 2021 (link), provided of course that phase III studies are successful.

ALKS-5461 failed to achieve its primary efficacy endpoint in two of three of its phase III studies. There were trends toward efficacy in the failed studies, but the results weren't significant. This was attributed by Alkermes to an "unusually high placebo response" in these studies. Alkermes tried to submit ALKS-5461 to the FDA for approval based on the one positive phase III study and the positive phase II studies, but the FDA said that they needed more data. You generally need at least two successful phase III studies for FDA approval. So Alkermes is now conducting one final phase III study. It should be completed in a few months. They intend to submit an NDA to the FDA by the end of this year. Tentative approval, provided that the final phase III study is successful, would be in 2018.

I've been watching ALKS-5461 since 2014. Drug development takes a really long time, unfortunately.

Johnson & Johnson is supposedly going to file an NDA for esketamine in 2018.